ClinicalTrials.gg
RecruitingNCT06866275STAT-2AUpdated Jul 30, 2026

Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)

A Phase 2 interventional study of KZ101 and Placebo in Autism Spectrum Disorder (ASD), sponsored by Children's Hospital of Orange County. Recruiting at 2 sites in United States. Open to male participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Children's Hospital of Orange County · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
5 Years to 14 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Planned enrollment
351st of 658
45 · median 50
Started
2025
with 31 others
Phase 2
101 of 773
14 open now
Primary completion
2028-04
later than 145 of 201 live
Registered
706th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 351st largest by planned enrollment of the 658 interventional ones that give a count, is one of 32 that started in 2025, is one of 101 in phase 2, reaches primary completion later than 145 of the 201 other live ones, and was the 706th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 5 Years to 14 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD. The current study, STAT-2A, will be a randomized, double-blind, crossover, 30-week study to evaluate the preliminary proof of concept, safety, and PK of suramin sodium (KZ101) with repeat dosing by IV infusion in males 5-14 years of age who have been diagnosed with ASD. The study will be conducted at approximately 3 sites contributing approximately 15 subjects per site. Total enrollment of approximately 45 subjects is planned to achieve approximately 36 participants completing the study.

Read the detailed description

After up to a 4-week screening period, participants will undergo 8 weeks of active or placebo treatment (Period 1), followed by an 8-week washout period, and then cross over to 8 weeks of placebo or active treatment (Period 2). Patients will be followed for 2 weeks after completion of Period 2. Two dosing groups are designated as Group A, who are randomly assigned to active treatment with KZ101 in Period 1 and saline in Period 2, and Group B, who are randomly assigned to saline infusion in Period 1 and active treatment with KZ101 in Period 2. Dosing in both periods will consist of 2 IV infusions of either saline (placebo) or KZ101 (active treatment), given 4 weeks apart.

03

Conditions studied

  • Autism Spectrum Disorder (ASD)

Keywords

  • Suramin
  • suramin sodium
04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Subject must meet all of the following criteria to be enrolled in this study.

  1. Male, aged 5-14 years
  2. Clinical diagnosis of ASD by criteria
  3. ADOS-2 ≥ 7 on the comparison score for Modules 2-4 (completed within the last 2 years).
  4. CGI-S ≥ 4 for socialization specific symptoms of ASD
  5. Leiter-3 non-verbal IQ > 70
  6. Standard score \< 75 on the Socialization Domain of the Comprehensive Interview Form of the Vineland Adaptive Behavior Scale Third Edition
  7. Subjects who are sexually active or potentially sexually active agree to use condoms with a spermicidal as a barrier method of during the treatment period and for at least 30 days after the last dose of study medication
  8. Subjects agree to wear sunscreen and to wear skin covering to the maximal degree tolerated by the child for the duration of the treatment period and for at least 30 days after the last dose of study medication
  9. Subjects must have a ≤ 90 minutes car ride from the study site
  10. English-speaking child and parent/guardian or caregiver
  11. Parent or their legal guardians must be willing to sign

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from the study.

    1. ASD diagnosis with underlying syndromic diagnosis (e.g., Fragile X, Angelman, Down's Syndrome, etc.)
    2. ≤ 5th percentile for weight
    3. Unable to tolerate venipuncture or urine collection
    4. Acute infection (e.g., upper respiratory tract infection, common cold, flu, strep, COVID-19)
    5. Severe co-morbid conditions (e.g., psychosis, seizures/epilepsy uncontrolled by medication, presence of severe visual or hearing impairment) that may interact with study procedures. Controlled epilepsy is allowed providing there has not been a breakthrough seizure in the past year.
    6. Any organ system dysfunction, especially liver (e.g., or AST ≥ 1.5x the ), kidney (estimated or eGFR \< 90 mL/min/1.73 m2; hematuria confirmed by urine microscopy [ > 5 red blood cells/high power field]; proteinuria [> 1+ that does not resolve on repeat testing or urine protein to creatinine ratio > 0.3]; and/or presence of any granular, mixed cellular, red blood cell, white blood cell, or muddy brown casts on urine microscopy), or heart or adrenal abnormalities
    7. Hospitalization within the previous 2 months from screening
    8. Initiation or change in pharmacotherapy within previous 2 months from screening
    9. Initiation or change in psychosocial interventions (formal behavioral, cognitive, or cognitive-behavior therapy) within previous 2 months from screening
    10. Plan to initiate or change pharmacotherapy or psychosocial interventions during the study
    11. Taking prescription medication that may interact adversely with KZ101 or expose the subject to increased risk of harm such as medications with plasma bound substances including sulfonamides, chlorpromazine, and anti-coagulants
    12. Currently enrolled in another clinical study or has received any treatment within 30 days of screening
    13. Taking > 3 medications addressing behavioral symptoms related to ASD (ie typical/atypical antipsychotics and alpha-adrenergic agonists) or comorbid medical conditions such as ADHD, anxiety, or depression. Anti-seizure medications and other medications not related to neurobehavioral symptoms do not count towards the total number of medications allowed.
    14. History of serious dermatological reactions
    15. History of allergy, intolerance, or photosensitivity to any drug
    16. Unable or unwilling to adhere to study requirements
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Drug followed by Placebo

    Drug: KZ101 · Drug: Placebo

  • Placebo comparator
    Placebo followed by Drug

    Drug: KZ101 · Drug: Placebo

Interventions

  • DrugSuraminStudies of SuraminSuramin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For active treatment with KZ101, a loading dose of 454 mg/m2 (salt-free) will be followed by a treatment dose of 363 mg/m2 (salt-free).

    Also known as: Suramin, Suramin sodium

  • DrugPlacebo

    Dosing in the placebo group will consist of a volume of normal saline equivalent to that given during the active treatment period for each participant.

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint - Vineland-3 Socialization Domain

    The primary efficacy endpoint will be the change in standard score on the Socialization Domain of the Comprehensive Interview Form of the Vineland Adaptive Behavior Scale Third Edition (Vineland-3), which includes subdomains for coping skills, play skills, and interpersonal relation skills.

    Time frame: Change from Screening to Week 8 (before washout) will be compared to change from Week 16 to Week 24 (after washout).

Secondary outcomes

  1. Secondary Efficacy Endpoint - Vineland-3, Additional Scores

    Vineland-3 Composite Score, Communication Domain Score, and Daily Living Skills Domain Score will also be assessed.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

  2. Secondary Efficacy Endpoint - Global Impresssion, Severity/Change

    Clinician Global Impression of Severity and Change, and Caregiver/Parent Global Impression of Severity and Change, will be collected and assessed weighted for socialization.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

  3. Secondary Efficacy Endpoint - Social Responsiveness Scale-2

    The Social Responsiveness Scale-2 (SRS-2) is a well-established tool to evaluate socialization that was also used in a prior pilot study.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

  4. Secondary Efficacy Endpoint - Aberrant Behavior Checklist, Second Edition (ABC-2)

    The ABC-2 provides measures of repetitive behaviors and includes domains of irritability, social withdrawal, stereotypy, hyperactivity, and inappropriate speech.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

  5. Secondary Efficacy Endpoint - Childhood Sleep Habits Questionnaire (CSHQ)

    As a large proportion of the adolescents with ASD population is highly impacted by sleep concerns, the CSHQ will be administered to investigate relationships between KZ101 and sleep.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

  6. Secondary Efficacy Endpoint - Parenting Stress Impact (PSI)

    Data from the PSI will be used to evaluate whether changes in symptoms in the ASD participant is associated with changes in parental stress throughout the study.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

  7. Secondary Efficacy Endpoint - Child Behavior Check List (CBCL)

    The CBCL is a parental measure of internalizing and externalizing behaviors as well as common DSM-5 conditions co-occurring with ASD.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

  8. Secondary Efficacy Endpoint - Ohio State University Autism Rating Scale, 5th Edition

    The Ohio State University Autism Rating Scale 5 (OARS-5) will provide three summary scores to be evaluated with KZ101 administration and placebo administration: autism symptom count, weighted mean severity score of autism symptoms, and impairment index based on level of support needed.

    Time frame: Secondary outcome measures will be used to assess change from Week 0 to Week 8 (before washout) and from Week 16 to Week 24 (after washout).

Other outcomes

  1. Pharmacokinetic (PK) Endpoints: Cmax

    Blood samples for measurement of KZ101 concentration in plasma will be collected and used to identify Peak Plasma Concentration (Cmax).

    Time frame: PK samples will be taken at week 0, 2, 4, 6, 8 (period 1); and 16, 18, 20, 22, 24, 26 (period 2 and follow up).

  2. Pharmacokinetic (PK) Endpoints: Area Under the Curve (AUC)

    Blood samples for measurement of KZ101 concentration in plasma will be collected, and area under the plasma concentration versus time curve (AUC) will be determined.

    Time frame: PK samples will be taken at week 0, 2, 4, 6, 8 (period 1); and 16, 18, 20, 22, 24, 26 (period 2 and follow up).

07

Study locations

2 of 2 sites recruiting
  • Children's Hospital Orange County, Thompson Autism and Neurodevelopmental Center
    Orange, California 92868, United States
    Recruiting
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
    Recruiting
08

References and documents

Publications

  • Naviaux RK, Zolkipli Z, Wang L, Nakayama T, Naviaux JC, Le TP, Schuchbauer MA, Rogac M, Tang Q, Dugan LL, Powell SB. Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. PLoS One. 2013;8(3):e57380. doi: 10.1371/journal.pone.0057380. Epub 2013 Mar 13. PubMed 23516405 ↗
  • Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, Naviaux RK. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. 2014 Jun 17;4(6):e400. doi: 10.1038/tp.2014.33. PubMed 24937094 ↗
  • Naviaux JC, Wang L, Li K, Bright AT, Alaynick WA, Williams KR, Powell SB, Naviaux RK. Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model. Mol Autism. 2015 Jan 13;6:1. doi: 10.1186/2040-2392-6-1. eCollection 2015. PubMed 25705365 ↗
  • Naviaux RK, Curtis B, Li K, Naviaux JC, Bright AT, Reiner GE, Westerfield M, Goh S, Alaynick WA, Wang L, Capparelli EV, Adams C, Sun J, Jain S, He F, Arellano DA, Mash LE, Chukoskie L, Lincoln A, Townsend J. Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. 2017 May 26;4(7):491-505. doi: 10.1002/acn3.424. eCollection 2017 Jul. PubMed 28695149 ↗

Individual participant data

Plan to share: No — There is no plan to share IPD at this time.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.

Of 68 non-industry phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 36 months is close to that.

Counting every sponsor, half of 83 studies reached it within 36 months; a quarter within 23 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 10, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06866275
Lead sponsor
Children's Hospital of Orange County
Collaborators
Kuzani Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Apr 9, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jul 30, 2026

Study contacts

Adrienne Moore, PhD
Contact
adrienne.moore@choc.org
714-288-7456
Aram Kim, MD
principal investigator · Thompson Autism and Neurodevelopmental Center, Children's Hospital of Orange County

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suramin

Start the discussion